1.The changes of bone biomechanical properties in osteoporosis
Journal of Medical Biomechanics 2017;32(4):E388-E392
Osteoporosis, a skeletal disorder of low bone density and disrupted bone architecture leading to fractures, is a common and costly condition among postmenopausal women. The biomechanical properties of bone are determined by the amount and quality of bone material and the arrangement of the material in space, mainly affected by the bone cortex, trabecular bone and collagen. When osteoporosis occurs, the cortex, trabecular bone and collagen all have the corresponding changes, which lead to the changes in biomechanical properties of bone. In this review, the changes of bone cortex, trabecular and collagen are summarized, to provide the comprehensive understanding about the changes of bone biomechanical properties in osteoporosis.
2.Methylation status of ZO-1 gene in patients with myelodysplastic syndrome.
Hui-Yuan KANG ; Chang WANG ; Li-Ping DOU ; Yun QING ; Xiao-Ping HAN ; Jing-Fen SUN ; Chun-Hui LIU ; Xue-Chun LU ; Yang LIU ; Li YU
Journal of Experimental Hematology 2008;16(1):70-73
The objective of this study was to investigate the methylation status of zonula occluden protein-1 (ZO-1) gene in patients with myelodysplastic syndrome (MDS) and to identify its roles in pathogenesis, development and classification of MDS. 85 patients with MDS and 30 healthy individuals were tested by methylation specific polymerase chain reaction (MS-PCR). The results indicated that no ZO-1 promoter methylation could be detected in healthy controls. methylation of ZO-1 gene promoter of bone marrow was found in 56.5% (48/85) MDS patients. The difference between these two kinds of subjects was statistically significant (p<0.05). The methylation status of ZO-1 gene promoter region in the subtypes of MDS was as following: RA (18/37, 48.6%), RAS (4/6, 67%), RCMD (19/30, 63%), RAEB (7/12, 58%). Every subtype of MDS patients had statistical difference from healthy people (p<0.05), but between the subtypes of MDS there were no significant statistical differences in the methylation status of ZO-1 gene, while the level of ZO-1 promoter methylation in group of RA was lower than that in other groups. It is concluded that the ZO-1 promoter region in bone marrow of MDS patient shows a hypermethylation status, which is specific for MDS. MDS is a common hematologic malignancy with clonal proliferation, it is difficult to differentiate from many other hematologic malignancies in clinical diagnosis. However, the change of ZO-1 gene methylation status is closely related to pathogenesis of MDS, therefore the ZO-1 gene as valuable diagnostic marker has important clinical significance. The ZO-1 gene may be a potential gene related to hematologic malignancies.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
DNA Methylation
;
Female
;
Humans
;
Male
;
Membrane Proteins
;
genetics
;
Middle Aged
;
Myelodysplastic Syndromes
;
genetics
;
Phosphoproteins
;
genetics
;
Promoter Regions, Genetic
;
genetics
;
Young Adult
;
Zonula Occludens-1 Protein
3.Expression of CXCR3 and CCR5 chemokine receptor in spleens of patients with primary immune thrombocytopenia.
Shu-fen ZHOU ; Ji MA ; Wei-dong HE ; Hui-ting QU ; Zong-tang LIU ; Juan-dong WANG ; Ai-xia DOU ; Ni ZHANG ; Cheng-shan GUO
Chinese Journal of Hematology 2012;33(11):944-947
OBJECTIVETo study CXCR3 and CCR5 chemokine receptor expression in spleens of patients with primary immune thrombocytopenia (ITP) and its clinical significance.
METHODSThe splenectomy specimens from 10 ITP patients (ITP group) and 8 patients with traumatic splenic rupture (normal control group) were studied. Immunohistochemistry (IHC) was used to study the positive rate of CXCR3 and CCR5. Western blot was performed to detect CXCR3 and CCR5 protein expression, while real-time polymerase chain reaction (RT-PCR) was conducted to analyze their mRNA expression.
RESULTSThe positive rate of CXCR3 and CCR5 were both higher in ITP group (90% and 100%, respectively) than those in control group (75% and 87.5%, respectively)(P < 0.05). The differences were statistically significant (P < 0.05). Protein and mRNA level of CXCR3 in ITP group were 3.0 and 3.5 times as high as those in control group, respectively. Those of CCR5 in ITP group were 1.2 and 1.7 times as high as those in control group, respectively.
CONCLUSIONHigh expression of CXCR3 and CCR5 may play a part in the splenic immune disorders in patients with ITP.
Adolescent ; Adult ; Case-Control Studies ; Child ; Female ; Humans ; Male ; Middle Aged ; Receptors, CCR5 ; metabolism ; Receptors, CXCR3 ; metabolism ; Spleen ; metabolism ; Thrombocytopenia ; immunology ; metabolism ; Young Adult
4.Comparison of early clinical outcomes between SuperCap and direct anterior approaches for total hip arthroplasty.
Wen-Ju CHANG ; Hai DING ; Fen-Dou LIU ; Xiang LI ; Xin-She ZHOU ; Li-Jia PEI ; Yang LIU ; Zhi-Yan WANG
China Journal of Orthopaedics and Traumatology 2023;36(11):1030-1035
OBJECTIVE:
To compare the short-term clinical efficacy of SuperCap approach and direct anterior approach in total hip arthroplasty.
METHODS:
Clinical data of 70 patients who underwent minimally invasive SuperCap approach and DAA THA in January 2016 to June 2017 were retrospective analyzed. These patients were divided into two groups:SuperCap approach group(SuperCap group) and direct anterior approach group(DAA group). There were 15 males and 15 females in SuperCap group, aged from 45 to 71 years old, and the follow-up time ranged from 24 to 30 months. There were 24 males and 16 females in Group B, aged from 51 to 76 years and the follow-up time ranged from 24 to 36 months. Hemoglobin level of the 3rd day after operation, transfusion rate, acetabular abduction angle, anteversion angle and creatine kinase level of the 3rd day after operation, Harris score of 3 months and the last time, VAS score of 1 week and the last time were recorded and compared. Complications were recorded at the final follow-up.
RESULTS:
All patients were followed up, the follow-up time of SuperCap group ranged from 24 to 30 months, that of DAA group ranged from 24 to 36 months. No significant differences were found in hemoglobin level on the 3rd day after operation, transfusion rate, Harris score or VAS score between two group (P>0.05). There was no significant difference in Harris score between 3 months after operation and the final follow-up in both groups (P>0.05). There were no significant difference in VAS scores of 6 weeks after operation and on the final follow-up neither(P>0.05). The level of creatine kinase in SuperCap group was significant lower than that in DAA group(P<0.05). Until the final follow-up, there was no significant difference in the incidence of complications between the two groups(P>0.05).
CONCLUSION
The clinical effect of minimally invasive SuperCap approach after total hip arthroplasty is comparable to that of DAA approach with less soft tissue injury. Patients can recover rapidly after operation and it is a safe and effective surgical approach for surgeons with short learning curve.
Male
;
Female
;
Humans
;
Middle Aged
;
Aged
;
Arthroplasty, Replacement, Hip
;
Retrospective Studies
;
Antiviral Agents
;
Treatment Outcome
;
Creatine Kinase
;
Hemoglobins